Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Change in Receivables: 2021-2024

Historic Change in Receivables for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Dec 2024 value amounting to $49,000.

  • Corvus Pharmaceuticals' Change in Receivables fell 254.29% to -$54,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$38,000, marking a year-over-year increase of 89.67%. This contributed to the annual value of $49,000 for FY2024, which is 108.72% up from last year.
  • Per Corvus Pharmaceuticals' latest filing, its Change in Receivables stood at $49,000 for FY2024, which was up 108.72% from -$562,000 recorded in FY2023.
  • Corvus Pharmaceuticals' 5-year Change in Receivables high stood at $507,000 for FY2021, and its period low was -$562,000 during FY2023.
  • Moreover, its 3-year median value for Change in Receivables was $49,000 (2024), whereas its average is -$144,000.
  • In the last 5 years, Corvus Pharmaceuticals' Change in Receivables slumped by 793.83% in 2023 and then soared by 108.72% in 2024.
  • Corvus Pharmaceuticals' Change in Receivables (Yearly) stood at $507,000 in 2021, then tumbled by 84.02% to $81,000 in 2022, then slumped by 793.83% to -$562,000 in 2023, then surged by 108.72% to $49,000 in 2024.